Genetic landscape and macro-evolution of co-circulating Coxsackieviruses A and Vaccine-derived Polioviruses in the Democratic Republic of Congo, 2008-2013.
Cell Line
Child
Democratic Republic of the Congo
/ epidemiology
Enterovirus C, Human
/ genetics
Enterovirus Infections
/ epidemiology
Evolution, Molecular
Humans
Phylogeny
Poliovirus
/ genetics
Poliovirus Vaccine, Oral
Prospective Studies
RNA, Viral
/ genetics
Recombination, Genetic
Retrospective Studies
Reverse Transcriptase Polymerase Chain Reaction
Sequence Analysis, DNA
Sequence Homology
Journal
PLoS neglected tropical diseases
ISSN: 1935-2735
Titre abrégé: PLoS Negl Trop Dis
Pays: United States
ID NLM: 101291488
Informations de publication
Date de publication:
04 2019
04 2019
Historique:
received:
10
01
2019
accepted:
27
03
2019
revised:
06
05
2019
pubmed:
20
4
2019
medline:
19
9
2019
entrez:
20
4
2019
Statut:
epublish
Résumé
Enteroviruses (EVs) are among the most common viruses infecting humans worldwide but only a few Non-Polio Enterovirus (NPEV) isolates have been characterized in the Democratic Republic of Congo (DR Congo). Moreover, circulating vaccine-derived polioviruses (PVs) [cVDPVs] isolated during multiple outbreaks in DR Congo from 2004 to 2018 have been characterized so far only by the sequences of their VP1 capsid coding gene. This study was carried to i) investigate the circulation and genetic diversity of NPEV and polio vaccine isolates recovered from healthy children and Acute Flaccid Paralysis (AFP) patients, ii) evaluate the occurrence of genetic recombination among EVs belonging to the Enterovirus C species (including PVs) and iii) identify the virological factors favoring multiple emergences of cVDPVs in DR Congo. The biological material considered in this study included i) a collection of 91 Sabin-like PVs, 54 cVDPVs and 150 NPEVs isolated from AFP patients between 2008 and 2012 in DR Congo and iii) a collection of 330 stool specimens collected from healthy children in 2013 in the Kasai Oriental and Maniema provinces of DR Congo. Studied virus isolates were sequenced in four distinct sub-genomic regions 5'-UTR, VP1, 2CATPase and 3Dpol. Resulting sequences were compared through comparative phylogenetic analyses. Virus isolation showed that 19.1% (63/330) healthy children were infected by EVs including 17.9% (59/330) of NPEVs and 1.2% (4/330) of type 3 Sabin-like PVs. Only one EV-C type, EV-C99 was identified among the NPEV collection from AFP patients whereas 27.5% of the 69 NPEV isolates typed in healthy children belonged to the EV-C species: CV-A13 (13/69), A20 (5/69) and A17 (1/69). Interestingly, 50 of the 54 cVDPVs featured recombinant genomes containing exogenous sequences in at least one of the targeted non-structural regions of their genomes: 5'UTR, 2CATPase and 3Dpol. Some of these non-vaccine sequences of the recombinant cVDPVs were strikingly related to homologous sequences from co-circulating CV-A17 and A20 in the 2CATPase region as well as to those from co-circulating CV-A13, A17 and A20 in the 3Dpol region. This study provided the first evidence uncovering CV-A20 strains as major recombination partners of PVs. High quality AFP surveillance, sensitive environmental surveillance and efficient vaccination activities remain essential to ensure timely detection and efficient response to recombinant cVDPVs outbreaks in DR Congo. Such needs are valid for any epidemiological setting where high frequency and genetic diversity of Coxsackieviruses A13, A17 and A20 provide a conducive viral ecosystem for the emergence of virulent recombinant cVDPVs.
Identifiants
pubmed: 31002713
doi: 10.1371/journal.pntd.0007335
pii: PNTD-D-18-02027
pmc: PMC6505894
doi:
Substances chimiques
Poliovirus Vaccine, Oral
0
RNA, Viral
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0007335Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Open Forum Infect Dis. 2015 Dec 09;3(1):ofv190
pubmed: 26788545
J Clin Microbiol. 2012 May;50(5):1650-8
pubmed: 22337981
Emerg Infect Dis. 2013 Oct;19(10):1583-9
pubmed: 24047933
J Virol. 2013 May;87(9):4907-22
pubmed: 23408630
J Virol. 2006 Jan;80(1):483-93
pubmed: 16352572
PLoS One. 2015 Aug 24;10(8):e0136700
pubmed: 26301510
MMWR Morb Mortal Wkly Rep. 2018 May 11;67(18):524-528
pubmed: 29746452
J Infect Dis. 2014 Nov 1;210 Suppl 1:S361-7
pubmed: 25316856
J Clin Microbiol. 1999 May;37(5):1288-93
pubmed: 10203472
Epidemiol Rev. 2000;22(2):298-316
pubmed: 11218380
J Infect Dis. 2008 May 15;197(10):1427-35
pubmed: 18419577
Pan Afr Med J. 2016 Jun 22;24:154
pubmed: 27642491
J Clin Microbiol. 2013 Mar;51(3):759-70
pubmed: 23254123
Mol Biol Evol. 2000 Aug;17(8):1251-8
pubmed: 10908645
J Med Virol. 2008 Oct;80(10):1790-8
pubmed: 18712819
J Clin Microbiol. 2005 Jan;43(1):242-9
pubmed: 15634978
J Virol Methods. 2008 May;149(2):277-84
pubmed: 18329732
J Clin Microbiol. 1996 Dec;34(12):2990-6
pubmed: 8940436
Viruses. 2011 Aug;3(8):1460-84
pubmed: 21994791
J Virol. 2008 Sep;82(17):8927-32
pubmed: 18579607
J Virol. 2005 Oct;79(20):12650-7
pubmed: 16188967
J Gen Virol. 2003 May;84(Pt 5):1223-1235
pubmed: 12692288
Sci Rep. 2016 Dec 13;6:38831
pubmed: 27958320
J Virol Methods. 2014 Mar;197:25-8
pubmed: 24321704
J Virol. 2011 May;85(9):4480-6
pubmed: 21345956
MMWR Morb Mortal Wkly Rep. 2014 Nov 14;63(45):1031-3
pubmed: 25393222
J Gen Virol. 2014 Jun;95(Pt 6):1255-1265
pubmed: 24558221
Virus Res. 2007 Sep;128(1-2):34-42
pubmed: 17485128
MMWR Morb Mortal Wkly Rep. 2018 Mar 16;67(10):300-305
pubmed: 29543791
J Gen Virol. 2012 Nov;93(Pt 11):2357-2362
pubmed: 22894922
J Med Virol. 2015 Mar;87(3):485-97
pubmed: 25163640
Curr Opin Infect Dis. 2003 Oct;16(5):375-81
pubmed: 14501988
Epidemiol Infect. 2005 Dec;133(6):1131-42
pubmed: 16274512
J Virol. 2004 Dec;78(24):13512-21
pubmed: 15564462
J Infect Dis. 2012 May 1;205(9):1363-73
pubmed: 22457288
J Infect Dis. 2011 Apr 1;203(7):898-909
pubmed: 21402542
Syst Biol. 2003 Oct;52(5):696-704
pubmed: 14530136
J Infect Dis. 2014 Nov 1;210 Suppl 1:S23-39
pubmed: 25316840
Food Environ Virol. 2016 Mar;8(1):27-33
pubmed: 26538420
J Gen Virol. 2009 Jul;90(Pt 7):1713-1723
pubmed: 19264596
J Gen Virol. 2014 Apr;95(Pt 4):868-873
pubmed: 24425417
J Gen Virol. 2001 Jan;82(Pt 1):79-91
pubmed: 11125161
PLoS One. 2011;6(9):e24823
pubmed: 21931857
J Virol Methods. 2011 Jun;174(1-2):128-30
pubmed: 21440569
MMWR Morb Mortal Wkly Rep. 2001 Mar 30;50(12):222-4
pubmed: 11300627
J Clin Microbiol. 2006 Nov;44(11):4077-84
pubmed: 16957032
J Gen Virol. 2005 Feb;86(Pt 2):445-451
pubmed: 15659764
PLoS Pathog. 2007 Dec;3(12):e191
pubmed: 18085822
J Gen Virol. 2006 Jan;87(Pt 1):119-28
pubmed: 16361424
J Neurovirol. 2005 Oct;11(5):424-33
pubmed: 16287683
Vaccine. 2017 Oct 9;35(42):5693-5699
pubmed: 28882442
PLoS Pathog. 2014 Apr 10;10(4):e1004052
pubmed: 24722315
PLoS Negl Trop Dis. 2014 Jul 31;8(7):e3052
pubmed: 25079078
J Paediatr Child Health. 2015 Feb;51(2):209-14
pubmed: 25074234
J Gen Virol. 2007 Sep;88(Pt 9):2520-6
pubmed: 17698662
J Med Virol. 2007 Apr;79(4):393-400
pubmed: 17311342
Mol Biol Evol. 2017 Sep 1;34(9):2422-2424
pubmed: 28472384
J Med Virol. 2008 Apr;80(4):670-9
pubmed: 18297723
Emerg Infect Dis. 2003 Jul;9(7):885-7
pubmed: 12899139
Mol Biol Evol. 2016 Jul;33(7):1870-4
pubmed: 27004904
Lancet. 2016 Aug 13;388(10045):717-27
pubmed: 26948435
J Clin Microbiol. 2006 Aug;44(8):2698-704
pubmed: 16891480
J Gen Virol. 2004 Nov;85(Pt 11):3205-3212
pubmed: 15483233
Proc Natl Acad Sci U S A. 2007 May 29;104(22):9457-62
pubmed: 17517601
PLoS One. 2014 Apr 02;9(4):e93737
pubmed: 24695547
J Gen Virol. 2007 Mar;88(Pt 3):849-58
pubmed: 17325357
PLoS Pathog. 2009 May;5(5):e1000412
pubmed: 19412342
J Infect Dis. 2014 Nov 1;210 Suppl 1:S50-61
pubmed: 25316874